Mouse models for core binding factor leukemia

被引:17
作者
Chin, D. W. L. [1 ]
Watanabe-Okochi, N. [1 ]
Wang, C. Q. [1 ,2 ]
Tergaonkar, V. [2 ]
Osato, M. [1 ,3 ,4 ,5 ]
机构
[1] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore
[2] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore
[3] ASTAR, Inst Bioengn & Nanotechnol, Singapore, Singapore
[4] Natl Univ Singapore, Dept Paediat, Singapore 117548, Singapore
[5] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
ACUTE MYELOID-LEUKEMIA; CBF-BETA-SMMHC; HEMATOPOIETIC STEM-CELLS; FUSION PROTEIN; MYELOPROLIFERATIVE DISORDER; DEFINITIVE HEMATOPOIESIS; EMBRYONIC LETHALITY; POINT MUTATIONS; MURINE MODEL; SELF-RENEWAL;
D O I
10.1038/leu.2015.181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RUNX1 and CBFB are among the most frequently mutated genes in human leukemias. Genetic alterations such as chromosomal translocations, copy number variations and point mutations have been widely reported to result in the malfunction of RUNX transcription factors. Leukemias arising from such alterations in RUNX family genes are collectively termed core binding factor (CBF) leukemias. Although adult CBF leukemias generally are considered a favorable risk group as compared with other forms of acute myeloid leukemia, the 5-year survival rate remains low. An improved understanding of the molecular mechanism for CBF leukemia is imperative to uncover novel treatment options. Over the years, retroviral transduction-transplantation assays and transgenic, knockin and knockout mouse models alone or in combination with mutagenesis have been used to study the roles of RUNX alterations in leukemogenesis. Although successful in inducing leukemia, the existing assays and models possess many inherent limitations. A CBF leukemia model which induces leukemia with complete penetrance and short latency would be ideal as a platform for drug discovery. Here, we summarize the currently available mouse models which have been utilized to study CBF leukemias, discuss the advantages and limitations of individual experimental systems, and propose suggestions for improvements of mouse models.
引用
收藏
页码:1970 / 1980
页数:11
相关论文
共 96 条
[1]   The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo [J].
Andreasson, P ;
Schwaller, J ;
Anastasiadou, E ;
Aster, J ;
Gilliland, DG .
CANCER GENETICS AND CYTOGENETICS, 2001, 130 (02) :93-104
[2]   AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation [J].
Bäsecke, J ;
Schwieger, M ;
Griesinger, F ;
Schiedlmeier, B ;
Wulf, G ;
Trümper, L ;
Stocking, C .
LEUKEMIA & LYMPHOMA, 2005, 46 (02) :265-272
[3]   Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse [J].
Buchholz, F ;
Refaeli, Y ;
Trumpp, A ;
Bishop, JM .
EMBO REPORTS, 2000, 1 (02) :133-139
[4]   Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model [J].
Cabezas-Wallscheid, Nina ;
Eichwald, Victoria ;
de Graaf, Jos ;
Loewer, Martin ;
Lehr, Hans-Anton ;
Kreft, Andreas ;
Eshkind, Leonid ;
Hildebrandt, Andreas ;
Abassi, Yasmin ;
Heck, Rosario ;
Dehof, Anna Katharina ;
Ohngemach, Svetlana ;
Sprengel, Rolf ;
Woertge, Simone ;
Schmitt, Steffen ;
Lotz, Johannes ;
Meyer, Claudius ;
Kindler, Thomas ;
Zhang, Dong-Er ;
Kaina, Bernd ;
Castle, John C. ;
Trumpp, Andreas ;
Sahin, Ugur ;
Bockamp, Ernesto .
EMBO MOLECULAR MEDICINE, 2013, 5 (12) :1804-1820
[5]   MN1 overexpression is an important step in the development of inv(16) AML [J].
Carella, C. ;
Bonten, J. ;
Sirma, S. ;
Kranenburg, T. A. ;
Terranova, S. ;
Klein-Geltink, R. ;
Shurtleff, S. ;
Downing, J. R. ;
Zwarthoff, E. C. ;
Liu, P. P. ;
Grosveld, G. C. .
LEUKEMIA, 2007, 21 (08) :1679-1690
[6]   The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia [J].
Castilla, LH ;
Garrett, L ;
Adya, N ;
Orlic, D ;
Dutra, A ;
Anderson, S ;
Owens, J ;
Eckhaus, M ;
Bodine, D ;
Liu, PP .
NATURE GENETICS, 1999, 23 (02) :144-146
[7]   Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia [J].
Castilla, LH ;
Perrat, P ;
Martinez, NJ ;
Landrette, SF ;
Keys, R ;
Oikemus, S ;
Flanegan, J ;
Heilman, S ;
Garrett, L ;
Dutra, A ;
Anderson, S ;
Pihan, GA ;
Wolff, L ;
Liu, PP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (14) :4924-4929
[8]   Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11 [J].
Castilla, LH ;
Wijmenga, C ;
Wang, Q ;
Stacy, T ;
Speck, NA ;
Eckhaus, M ;
MarinPadilla, M ;
Collins, FS ;
WynshawBoris, A ;
Liu, PP .
CELL, 1996, 87 (04) :687-696
[9]   Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter [J].
Chen, Michael J. ;
Yokomizo, Tomomasa ;
Zeigler, Brandon M. ;
Dzierzak, Elaine ;
Speck, Nancy A. .
NATURE, 2009, 457 (7231) :887-891
[10]   Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia [J].
Cheng, Chi Keung ;
Li, Libby ;
Cheng, Suk Hang ;
Lau, Kin Mang ;
Chan, Natalie P. H. ;
Wong, Raymond S. M. ;
Shing, Matthew M. K. ;
Li, Chi Kong ;
Ng, Margaret H. L. .
BLOOD, 2008, 112 (08) :3391-3402